文献速递哮喘慢阻肺呼吸道感染

呼吸道病毒感染中IFN-β应答动态:治疗策略启示

Dynamics of IFN-β Responses during Respiratory Viral Infection. Insights for Therapeutic Strategies.
PubMed 文献 · Am J Respir Crit Care Med · 2020-01-01

研究探讨外源性IFN-β在病毒感染前或后给予对流感病毒感染的影响,使用健康对照和COPD患者的巨噬细胞及支气管上皮细胞。结果显示感染前给予IFN-β可显著减少感染细胞百分比,且抑制作用可持续一定时间,提示间歇预防性给药的潜力。

要点

  • 感染前给予IFN-β可显著降低流感病毒感染细胞百分比。
  • IFN-β对健康对照和COPD患者的抑制作用相似。
  • IFN-β不诱导炎症因子,但减少IL-1β产生。

核心结论

  • 体外模型提示间歇预防性给予外源性IFN-β可能调节病毒感染。

研究设计与样本

  • 从健康对照和COPD患者分离单核细胞衍生巨噬细胞、肺泡巨噬细胞和原代支气管上皮细胞,在流感病毒感染前或后给予IFN-β刺激。

主要发现

  • 感染前加IFN-β使MDMs、肺泡巨噬细胞和PBECs中核蛋白1阳性细胞百分比分别降低85%、56%和66%(P < 0.05)。
  • 去除IFN-β后抑制作用在MDMs中持续24小时,至1周仍维持但减弱;在PBECs中持续72小时。
  • 健康对照与COPD患者间抑制作用相似。
  • IFN-β不诱导MDMs或PBECs产生炎症因子,但减少PBECs中流感诱导的IL-1β产生。

临床怎么用

  • 提示未来临床试验可考虑间歇预防性给予IFN-β以调节呼吸道病毒感染。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Viral infections are major drivers of exacerbations and clinical burden in patients with asthma and chronic obstructive pulmonary disease (COPD). IFN-β is a key component of the innate immune response to viral infection. To date, studies of inhaled IFN-β treatment have not demonstrated a significant effect on asthma exacerbations.Objectives: The dynamics of exogenous IFN-β activity were investigated to inform on future clinical indications for this potential antiviral therapy.Methods: Monocyte-derived macrophages (MDMs), alveolar macrophages, and primary bronchial epithelial cells (PBECs) were isolated from healthy control subjects and patients with COPD and infected with influenza virus either prior to or after IFN-β stimulation. Infection levels were measured by the percentage of nucleoprotein 1-positive cells using flow cytometry. Viral RNA shedding and IFN-stimulated gene expression were measured by quantitative PCR. Production of inflammatory cytokines was measured using MSD.Measurements and Main Results: Adding IFN-β to MDMs, alveolar macrophages, and PBECs prior to, but not after, infection reduced the percentage of nucleoprotein 1-positive cells by 85, 56, and 66%, respectively (P < 0.05). Inhibition of infection lasted for 24 hours after removal of IFN-β and was maintained albeit reduced up to 1 week in MDMs and 72 hours in PBECs; this was similar between healthy control subjects and patients with COPD. IFN-β did not induce inflammatory cytokine production by MDMs or PBECs but reduced influenza-induced IL-1β production by PBECs.Conclusions:In vitro modeling of IFN-β dynamics highlights the potential for intermittent prophylactic doses of exogenous IFN-β to modulate viral infection. This provides important insights to aid the future design of clinical trials of IFN-β in asthma and COPD.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Watson A, Spalluto CM, McCrae C, et al. Dynamics of IFN-β Responses during Respiratory Viral Infection. Insights for Therapeutic Strategies. Am J Respir Crit Care Med. 2020. PMID: 31461630. doi:10.1164/rccm.201901-0214OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。